Kirin Holdings(KNBWY)

Search documents
Is Kirin (KNBWY) Stock Undervalued Right Now?
ZACKS· 2025-02-12 15:46
Core Viewpoint - The article emphasizes the importance of value investing as a successful strategy across various market conditions, highlighting the use of fundamental analysis and valuation metrics to identify undervalued stocks. Group 1: Value Investing Strategy - Value investing is a popular stock market trend that focuses on identifying stocks believed to be undervalued by the market through fundamental analysis and traditional valuation metrics [2] - Zacks has developed a Style Scores system to identify stocks with specific traits, particularly in the "Value" category, which is of interest to value investors [3] Group 2: Kirin (KNBWY) Analysis - Kirin (KNBWY) has a Zacks Rank of 2 (Buy) and an A grade for Value, indicating it is a strong candidate for value investors [4] - The stock is currently trading at a P/E ratio of 11.29, significantly lower than its industry's average of 13.82, suggesting it may be undervalued [4] - KNBWY has a P/S ratio of 0.67, compared to the industry's average P/S of 1.27, further indicating its potential undervaluation [5] - The combination of these metrics positions Kirin as one of the market's strongest value stocks, especially considering its positive earnings outlook [6]
AlphaMeld Corporation Expands Collaboration with Kyowa Kirin for Enterprise-Wide Access to Drug Discovery Platform
GlobeNewswire News Room· 2025-01-28 15:00
Core Insights - AlphaMeld Corporation has announced the continuation and expansion of its collaboration with Kyowa Kirin Co., Ltd., enhancing access to its AI-powered AlphaMeld® platform for drug discovery and development [1][2][4] Group 1: Collaboration Details - The expanded partnership allows Kyowa Kirin's global research and development teams to integrate the AlphaMeld platform into their workflows, facilitating data-driven decisions and streamlining the drug development process [4][5] - This collaboration builds on previous successes and highlights Kyowa Kirin's commitment to leveraging advanced AI technologies to address unmet medical needs globally [2][3] Group 2: Technological Impact - The AlphaMeld platform empowers stakeholders involved in early drug discovery, target identification, competitive intelligence, and clinical trial optimization by extracting actionable insights from diverse datasets [2][4] - The integration of the AlphaMeld platform is expected to enable Kyowa Kirin to identify novel therapeutic opportunities with increased speed, precision, and probability of clinical success [5][6] Group 3: Company Backgrounds - AlphaMeld Corporation is a leader in applying AI, machine learning, and generative AI tools to revolutionize drug discovery, with a mission to expedite transformative therapies for diseases with unmet medical needs [6] - Kyowa Kirin has over 70 years of experience in drug discovery and biotechnology innovation, focusing on developing next-generation therapies for high unmet medical needs [7]
KNBWY vs. DEO: Which Stock Is the Better Value Option?
ZACKS· 2025-01-27 17:41
Core Insights - Kirin Holdings Co. (KNBWY) is currently rated higher than Diageo (DEO) based on Zacks Rank, with KNBWY at 2 (Buy) and DEO at 4 (Sell) [3] - KNBWY exhibits stronger earnings estimate revision activity compared to DEO, indicating a more favorable analyst outlook for KNBWY [3][7] Valuation Metrics - KNBWY has a forward P/E ratio of 11.13, significantly lower than DEO's forward P/E of 18.80, suggesting KNBWY is undervalued [5] - The PEG ratio for KNBWY is 0.86, while DEO's PEG ratio is considerably higher at 4.21, indicating KNBWY's expected earnings growth is more favorable relative to its valuation [5] - KNBWY's P/B ratio stands at 1, compared to DEO's P/B ratio of 5.73, further supporting the notion that KNBWY is undervalued [6] Value Grades - KNBWY holds a Value grade of A, while DEO has a Value grade of F, highlighting KNBWY's superior valuation metrics [6]
Should Value Investors Buy Kirin (KNBWY) Stock?
ZACKS· 2025-01-27 15:41
Core Insights - The article emphasizes the importance of value investing, which focuses on identifying undervalued companies in the market [2] - Zacks has developed a Style Scores system to highlight stocks with specific traits, particularly for value investors [3] Company Overview: Kirin (KNBWY) - Kirin currently has a Zacks Rank of 2 (Buy) and an A for Value, indicating strong potential for value investors [4] - The stock has a P/E ratio of 11.28, significantly lower than the industry average P/E of 14.38 [4] - Over the past 12 months, Kirin's Forward P/E has fluctuated between 11.13 and 14.14, with a median of 12.56 [4] - The P/S ratio for Kirin is 0.66, compared to the industry average P/S of 1.42, suggesting it is undervalued [5] - These metrics indicate that Kirin is likely undervalued, making it an attractive option for value investors [6]
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
GlobeNewswire News Room· 2024-11-20 22:00
Collaboration Overview - Kura Oncology and Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib, a selective oral menin inhibitor for treating acute myeloid leukemia (AML) and other hematologic malignancies [1] - Kura will receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments [1][2] - The collaboration includes a 50/50 profit share in the U.S., with Kura leading U.S. development and commercial activities, while Kyowa Kirin has exclusive commercialization rights outside the U.S. [1][3][4] Financial and Commercial Terms - Kura is eligible for additional milestone payments totaling $741 million, bringing the total potential payments to $1.161 billion, including the opt-in for solid tumor indications [2] - In the U.S., Kura will book sales and lead commercial strategy, sharing profits and losses equally with Kyowa Kirin [3][9] - Outside the U.S., Kyowa Kirin will lead commercialization, and Kura will receive tiered double-digit royalties on net product sales [4][9] Development and Clinical Plans - The companies will jointly pursue a broad development program targeting acute leukemias, including frontline indications, combinations with targeted therapies, and post-transplant maintenance settings [1][6] - Kura anticipates that the collaboration funding, combined with its current cash balance, will support the AML program through commercialization in frontline combination therapy [1][8] - The companies plan to launch multiple Phase 2 and Phase 3 studies of ziftomenib in AML and other hematologic malignancies over the next several years [10] Regulatory and Market Potential - Ziftomenib has received Breakthrough Therapy Designation from the FDA for the treatment of relapsed/refractory NPM1-mutant AML, a mutation associated with poor outcomes [6][14] - Kura expects to submit a New Drug Application (NDA) in 2025 and initiate registrational Phase 3 frontline studies in both fit and unfit AML patient populations in 2025 [6][8] - The U.S. market opportunity for ziftomenib in the frontline setting is estimated at up to $3 billion annually [8] Additional Collaboration Details - Kura will fund development costs until the end of 2028, after which both companies will share costs at a 50:50 ratio [10] - Kyowa Kirin has an option to participate in the development and commercialization of ziftomenib in gastrointestinal stromal tumors (GIST) and other solid tumor indications, with Kura eligible for additional upfront and milestone payments totaling $228 million if the option is exercised [11] - The collaboration excludes Kura's ongoing efforts to advance next-generation menin inhibitor drug candidates targeting oncology indications, diabetes, and other metabolic diseases [11]
Kirin Holdings: More Patience Is Required
Seeking Alpha· 2024-10-09 20:25
Asia Value & Moat Stocks is a research service for value investors seeking Asia-listed stocks with a huge gap between price and intrinsic value, leaning towards deep value balance sheet bargains (i.e., buying assets at a discount e.g., net cash stocks, net-nets, low P/B stocks, sum-of-the-parts discounts) and wide moat stocks (i.e., buying earnings power at a discount in great companies like "Magic Formula" stocks, high-quality businesses, hidden champions and wide moat compounders). Sign up here to get sta ...
Kyowa Kirin Announces Top-line Data from Rocatinlimab Phase 3 ROCKET HORIZON Trial for Adults with Moderate to Severe Atopic Dermatitis
Prnewswire· 2024-09-25 11:00
Rocatinlimab Met Co-Primary Endpoints of vIGA-ADTM 0/1 with a ≥ 2-Point Reduction from Baseline, EASI-75, and All Key Secondary Endpoints HORIZON is the First of Eight Phase 3 Trials in the ROCKET Program TOKYO, Sept. 25, 2024 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (Kyowa Kirin) (TSE:4151) (President and CEO: Masashi Miyamoto) announced top-line results of the Phase 3 ROCKET HORIZON trial of rocatinlimab, an investigational therapy targeting the OX40 receptor. HORIZON met its co-primary endpoints: achievemen ...
Kyowa Kirin to Present New Research Spotlighting Global Efforts to Advance Science and Patient Care in X-linked Hypophosphatemia at ASBMR Annual Meeting
Prnewswire· 2024-09-19 12:00
Core Insights - Kyowa Kirin will present new research on burosumab treatment for X-linked hypophosphatemia (XLH) at the ASBMR 2024 annual meeting, highlighting real-world experiences and the disease's impact on patients [1][3] Research Presentation Details - An oral presentation titled "Patient reported outcomes (PRO) from a real-world study of burosumab treatment in adults with X-linked hypophosphatemia in the UK" will be delivered by Judith Bubbear, MD, on September 28 [2] - Multiple poster presentations will cover various aspects of burosumab's effectiveness and patient experiences, including comparisons with conventional therapy and biochemical measurements [4][5] Disease Overview - X-linked hypophosphatemia is a rare genetic disease characterized by low phosphorus levels, leading to bone and muscle issues in both children and adults [6] - The condition results from excess production of fibroblast growth factor 23 (FGF23), causing the body to excrete too much phosphorus [6] Treatment Information - CRYSVITA (burosumab) is a monoclonal antibody that inhibits FGF23, helping to restore phosphorus reabsorption in the kidneys and enhance vitamin D production [7][8] - It is indicated for the treatment of XLH in patients aged 6 months and older [8] Company Background - Kyowa Kirin is a Japan-based global specialty pharmaceutical company focused on drug discovery and biotechnology innovation, with over 70 years of experience [20]
Kyowa Kirin to end distribution of Fareston (toremefine) in the United States
Prnewswire· 2024-08-23 15:05
PRINCETON, N.J., Aug. 23, 2024 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company based in Japan, is announcing that it will no longer distribute or fulfill orders for Fareston (toremefine) 60 mg tablets in the United States, effective August 31, 2024. This decision aligns with the company's Vision for 2030 and its focus on the discovery, development and delivery of novel therapies for patients. Kyowa Kirin has previou ...
KNBWY or DEO: Which Is the Better Value Stock Right Now?
ZACKS· 2024-08-12 16:42
Investors looking for stocks in the Beverages - Alcohol sector might want to consider either Kirin Holdings Co. (KNBWY) or Diageo (DEO) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors stocks with strong ...